Evidence map›Paper›PMID 31014449›Full record

ReviewDeutsches Arzteblatt international2019

Corneal Collagen Cross-Linking in the Stabilization of Keratoconus.

Philip Maier, Thomas Reinhard, Markus Kohlhaas

Abstract readReview
In one paragraph

Review in Deutsches Arzteblatt international, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 38 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Keratoconus: imaging modalities and management.Medical hypothesis, discovery & innovation ophthalmology journal · 2024
    Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. [Stage-appropriate treatment of keratoconus].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2021
    Article
  18. Are changes in visual acuity and astigmatism after corneal cross-linking (CXL) in keratoconus predictable?Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2021
    Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Philip MaierEye Center at the University of Freiburg Medical Center, Albert Ludwig University Freiburg; Department of Ophthalmology, St. Johannes Hospital, Dortmund.
Thomas Reinhard
Markus Kohlhaas
University of Freiburg · DEEye Center · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundKeratoconus is a slowly progressive ectatic deformity of the cornea with a prevalence of 200 to 400 cases per 100 000 persons. The cornea is thinner than normal and irregularly warped; irregular astigmatism and myopia result. Riboflavin-UVA crosslinking (collagen cross-linking) makes corneal tissue more rigid through a photochemical effect and can stop the progression of the disease.

methodsThis review is based on relevant publications retrieved by a selective search in Medline, as well as on meta-analyses, Cochrane Reviews, and reports of national and international health care institutions.

resultsPertinent randomized controlled trials (RCTs) have shown that cross-linking prevents the progression of keratoconus to a statistically significant extent, as determined by measurement of topographic parameters. In the largest RCT to date (fol- low-up of 100 eyes for three years), the maximal corneal refractive power increased by 1.75 ± 0.38 diopters in the control group and decreased by -1.03 ± 0.19 diopters in the cross-linking group (p <0.001). This was also the only trial in which data were reported on the patient-relevant endpoint of uncorrected visual acuity, which mildly improved in the cross-linking group (-0.15 ± 0.06 logMAR, p = 0.009). Serious complications of cross-linking are known to date only from a few reports of individual cases. Cohort studies with follow-up times of up to ten years have shown that the condition can continue to progress after cross-linking, especially in younger patients.

conclusionCross-linking is the first available treatment for keratoconus that can improve the natural course of the disease.

Indexed as

CollagenCross-Linking ReagentsHumansKeratoconusRandomized Controlled Trials as TopicCollagenCross-Linking Reagents

Identifiers

PMID31014449
PMCPMC6503175
OpenAlexW2921773221

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.